Genomtec (GMT) Investor Update summary

Key updates

• No substantive information or updates provided in the available content.

Management and organizational updates

• International team of 20 experts operates from Wrocław and Kent, UK, led by co-founder Miron Tokarsky, with expertise in molecular biology, finance, and photonics.

• Recent organizational restructuring aligns with the M&A process, creating dedicated subsidiaries for Genomtec ID, Onco SNAAT, and food safety projects to accelerate transactions and increase value.

Technology and product development

• Genomtec specializes in advanced genetic diagnostics, focusing on point-of-care solutions using proprietary SNAAT and LAMP isothermal amplification technologies.

• LAMP technology enables rapid, highly specific DNA/RNA detection at femtogram levels, with results in under 30 minutes and high resistance to sample inhibitors.

• Genomtec ID platform allows multiplexed, mobile, low-cost diagnostics, with ongoing improvements in heating system stability and test speed.